EUVIMEDEUVIMED entdecken
Crossref

Seroprevalence of Neutralizing Antibodies Against Human Adenovirus Genotypes Associated With Acute Respiratory Infections in Healthy South Korean Individuals (2019)

Ji Heun Jeong iD, So Yun Park, Hye Yun Jeong, Ye Eun Lee, Seo Hee Jung, Soon-Hwan Kwon iD

Journal of Medical Virology · 2026-06 · 98 (6)

DOI: 10.1002/jmv.70995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 29.05.2026. Verfasst von Ji Heun Jeong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, Armed Forces Medical Research Institute, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Adenoviruses, Human, Antibodies, Neutralizing, Respiratory Tract Infections, Antibodies, Viral. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Institute of Health (NIH) research project, Korea Health Technology R&D Project, Korea Health Industry Development Institute (KHIDI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human adenoviruses (HAdVs) are major etiological agents of acute respiratory infections (ARIs); however, population‐level immunity to primary genotypes in South Korea remains unclear. We applied a micro‐neutralization enzyme‐linked immunosorbent assay to assess neutralizing antibodies against HAdV‐3, ‐4, ‐7, and ‐55 in sera from 800 healthy individuals. Seropositivity was highest for HAdV‐3 (79.3%), followed by HAdV‐4 (47.3%), HAdV‐55 (30.1%), and HAdV‐7 (21.3%). HAdV‐3 exhibited both high prevalence and titers, whereas HAdV‐4 exhibited predominantly low titers. HAdV‐7 and ‐55 exhibited lower seroprevalence, with moderate nAb levels observed among seropositive individuals. Seroprevalence was similar across age and sex, except for a significant decline in HAdV‐55 among individuals aged ≥ 50 years. These findings provide large‐scale seroepidemiological data on ARI‐associated HAdV genotypes in South Korea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenoviruses, HumanAntibodies, NeutralizingRespiratory Tract InfectionsAntibodies, ViralAdenovirus Infections, HumanHumansSeroepidemiologic StudiesMaleFemaleRepublic of KoreaMiddle AgedGenotypeAdultAgedYoung AdultChildAdolescentChild, PreschoolEnzyme-Linked Immunosorbent AssayAged, 80 and over

Stichwörter der Autor:innen

HAdV‐3HAdV‐4HAdV‐55HAdV‐7human adenovirusmulti‐type seropositivityneutralizing antibodyseroprevalence

Substanzen

Antibodies, NeutralizingAntibodies, Viral

Autor:innen und Institutionen

  • Department of Infectious Disease, Armed Forces Medical Research Institute, Daejeon, Republic of Korea.
  • Department of Anatomy, College of Medicine, Konyang University, Daejeon, Republic of Korea.

ORCID-Profile: Ji Heun Jeong, Soon-Hwan Kwon

Förderung

  • National Institute of Health (NIH) research project
  • Korea Health Technology R&D Project
  • Korea Health Industry Development Institute (KHIDI)
  • Ministry of Health & Welfare, Republic of Korea

Zitieren

APA

Jeong, J. H., Park, S. Y., Jeong, H. Y., Lee, Y. E., Jung, S. H., & Kwon, S. H. (2026). Seroprevalence of Neutralizing Antibodies Against Human Adenovirus Genotypes Associated With Acute Respiratory Infections in Healthy South Korean Individuals (2019). Journal of Medical Virology, 98(6). https://doi.org/10.1002/jmv.70995

Vancouver

Jeong JH, Park SY, Jeong HY, Lee YE, Jung SH, Kwon SH. Seroprevalence of Neutralizing Antibodies Against Human Adenovirus Genotypes Associated With Acute Respiratory Infections in Healthy South Korean Individuals (2019). Journal of Medical Virology. 2026;98(6). doi:10.1002/jmv.70995

BibTeX
@article{Jeong2026,
  author = {Jeong, Ji Heun and Park, So Yun and Jeong, Hye Yun and Lee, Ye Eun and Jung, Seo Hee and Kwon, Soon-Hwan},
  title = {Seroprevalence of Neutralizing Antibodies Against Human Adenovirus Genotypes Associated With Acute Respiratory Infections in Healthy South Korean Individuals (2019)},
  journal = {Journal of Medical Virology},
  year = {2026},
  volume = {98},
  number = {6},
  doi = {10.1002/jmv.70995}
}
Kostenlos starten →